Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the efficacy, carbidopa dose response and
safety of ODM-101, a new combination of levodopa, carbidopa and entacapone in the treatment
of Parkinson's disease (PD) patients with end-of-dose motor fluctuations.